AlgaeAid is an inulin-integrating hydrogel dressing aimed at the treatment of second and third-degree burns and infected chronic wounds, which lack an optimal dressing. Currently, the vast majority of dressings for burns and chronic wounds are not optimal for all kinds of wounds. AlgaeAid's implementation of inulin separates it from the rest of the antibiotic hydrogels. The inulin allows for increased water retention within a hydrogel because it becomes osmotically active when combined with a liquid. As this property allows plants to remain hydrated and withstand dry and cold temperatures, increasing water retention. The flexibility that inulin provides makes AlgaeAid more universally applicable and allows for the treatment of wounds with more fluid expulsion which makes it effective against superbugs such as MRSA and can be readily sourced from a wide variety of algae and plant sources, including chicory, algae, and 35 other plant species.

This disclosure provides a hydrocolloid having a super absorbent material chemically bonded either directly or indirectly to a peroxide. The peroxide is within the hydrocolloid and the peroxide is in an amount of 0.05% to 2% by weight within the hydrocolloid.

A wound healing composition and method for treating acute and chronic wounds and skin conditions includes a wound healing composition or formulation including a mixture of buckwheat honey, methylglyoxal and bacitracin.

The present disclosure provides fibrous composition comprising a soluble or a dispersible N-halamine, for example 1-chloro-2,2,5,5-tetramethyl-4-imidazolidinone (i.e., compound I). Additionally, the disclosure provides methods for producing the fibrous compositions comprising a soluble or a dispersible N-halamine as well as methods for protecting a person from an infection using the fibrous compositions comprising a soluble or a dispersible N-halamine. The compositions and methods according to the present disclosure provide several advantages, such as stability, less time to provide sufficient antimicrobial inactivation, and are inexpensive and require lower amount of active concentrations to be effective.

A composition has hyaluronic acid and one or more materials as an admixture. The hyaluronic acid is derived from a fascia tissue layer of an alligator, the fascia layer located below a hide and above muscle tissue. The one or more materials as the admixture to the hyaluronic acid can be a carrier, diluent or excipient. The hyaluronic acid is extracted from the fascia tissue layer in the form of an oil having an oily viscosity with a molecular weight of 30,000 or greater. The oil extracted includes the hyaluronic acid and includes sodium or salts of hyaluronic acid. The oil extracted is anti-inflammatory to human tissue.

Methods and compositions for treating various indications by lessening oxidative stress in a patient are provided. A pharmaceutical composition comprises between about 0.001% to about 10.0%, or more specifically between about 0.015% to about 5%, sodium iodide or catalase by weight. The iodine ion or the catalase dissociates hydrogen peroxide into water and molecular oxygen to interrupt biological events that result in negative side effects. The pharmaceutical composition further comprises in some cases a reducing agent or various carrier materials. The pharmaceutical composition is in some cases formulated for a variety of delivery methods.

Methods for forming and incorporating microparticles containing one or more active agents into adhesives are described. The methods involve spray drying a liquid of the one or more active agents and obtaining the active agent in a particulate form. The dry powder is then blended or otherwise incorporated with the adhesive of interest. Also described are various medical products utilizing the adhesive and one or more active agents in microparticle form, and related methods of use.

Polyhydric polymers may be converted to derivatives thereof by reaction with divinyl sulfone to provide vinyl sulfone substituted polymers, where the polymers may additionally be further derivatized, including crosslinked, and the crosslinked and non-crosslinked derivatives may be used in biomedical and other applications.

Disclosed herein is a plasma treatment method comprising: providing a plasma source and a screen comprising a hydrogel and positioning the screen between the plasma source and a surface of a target to be treated with the plasma such that substantially all of the plasma from the plasma source passes through the screen prior to contacting the surface of the target and the screen reduces the concentration of one or more species from the plasma; and/or contacting a surface of a target to be treated with the gel composition comprising a gel forming material and a liquid phase comprising plasma activated liquid.

An aqueous composition with a higher-than-neutral pH includes a significant amount of one or more surfactants and large amounts of osmotically active solutes. This composition, as well as an acidic counterpart and solid materials, can be used in a variety of applications such as wound care, oral care, medical equipment reprocessing, healthcare acquired infection and implant treatment.